anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aimed to investigate the effects of mild therapeutic hypothermia combined with stereotactic aspiration of spontaneous intracerebral hematoma on neurological function, inflammatory markers, cerebral hematoma, and cerebral edema in patients with severe cerebral hemorrhage. The clinical data of 86 patients with severe cerebral hemorrhage treated at our hospital between March 2020 and January 2022 were retrospectively analyzed. The patients were grouped according to their treatment plans: the control group consisted of 40 patients who underwent stereotactic aspiration of the spontaneous intracerebral hematoma, whereas the study group consisted of 46 patients who received adjuvant mild therapeutic hypothermia in addition to the aforementioned treatment. Clinical efficacy, neurological function (NIHSS score), daily living ability (BI score), cerebral hematoma, cerebral edema, cerebral hemodynamics (PI, RI, Vm, Vd), inflammatory markers (IL-6, IL-8, TNF-α, hs-CRP), oxidative stress indicators (SOD, MDA, 8-iso-PGF2α), serum-related factors (MMP-9, ICAM-1, ET-1, NO), and prognosis were compared between the groups. The total efficacy rate in the study group (95.65%) was significantly higher than that in the control group (77.50%) (P < 0.05). Post-treatment NIHSS scores, intracranial hematoma volume, perihematoma edema volume, cerebral edema volume, RI, serum IL-6, IL-8, TNF-α, hs-CRP, MDA, and 8-iso-PGF2α levels were significantly lower in both groups, with the study group showing even greater reductions. The BI score and PI, Vm, Vd, SOD, and NO levels were significantly higher in the study group (P < 0.05). At the 6-month follow-up, the prognosis of patients in the intervention group was significantly better than that of patients in the control group (P < 0.05). The combination of mild therapeutic hypothermia with stereotactic aspiration of a spontaneous intracerebral hematoma has demonstrated efficacy in the treatment of severe cerebral hemorrhage. This approach effectively reduces cerebral hematoma and edema, improves daily living ability, alleviates neurological deficits, regulates cerebral hemodynamics, suppresses inflammatory responses and oxidative stress, modulates serum-related factor levels, and enhances patient prognosis.
Pregnancy Category B: In a study in which rats were dosed from day 14 (females) or day 60 (males) prior to mating through the period of organogenesis, a slightly increased incidence of skeletal variations was observed at doses of 8 mg/kg/day (3 times the Maximum Recommended Human Dose [MRHD] on a mg/m2 basis) and 16 mg/kg/day. In a study in which pregnant rats were dosed from the beginning of organogenesis through day 21 post-partum, pup weights were decreased at 8 and 16 mg/kg/day, but no adverse effects on other postnatal developmental parameters were seen. The doses causing the above effects in rats produced slight maternal toxicity. No major malformations were caused in rats given up to 16 mg/kg/day. No drug related teratogenic effects were observed in rabbits given up to 40 mg/kg/day (32 times the MRHD on a mg/m2 basis) during the period of organogenesis.

There are no adequate and well-controlled studies of galantamine hydrobromide in pregnant women. Galantamine hydrobromide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The invention belongs to the field of ethnic medicines and discloses an externally used Yao medicine composition for treating ganglion and a preparation method thereof. The composition comprises the following raw materials in parts by weight: 3-30 parts of root of clematis chinensis osbeck, 1-10 parts of pseudo-ginseng and 2-20 parts of herb of gynura divaricate(L.)DC. The dosage form of the composition is powder. The composition is mixed with medicinal liquor and is applied. The preparation method comprises the processes of grinding, baking and sterilizing the raw medicines, thus preparing the powder. Clinical tests show that the Yao medicine composition has the specific functions of softening hardness to dissipate stagnation, breaking stasis to diminish swelling and activating blood to promote menstruation, can soften and dissipate ganglion, has definite, quick and stable curative effects, does not have toxic or side effect and is a good medicine for treating ganglion.
The invention discloses a biological disinfectant with safety, high efficiency and low irritation. One milliliter of the biological disinfectant comprises the following components: 0.5 to 10 milligrams of epsilon-polylysine, 1 to 20 milligrams of glycerol, 0.8 to 16 milligrams of dodecyl dimethyl betaine and the balance of buffer solution with the pH value of 6.0 t 7.5. The biological disinfectant can be used for disinfecting hand skin, the surfaces of objects and the like. The sterilizing log value of the biological disinfectant on Escherichia coli and candida albicans within 3 minutes is more than 3. The sterilizing log value of the biological disinfectant on pseudomonas aeruginosa and staphylococcus aureus is more than 6. As the contact lasts, a disinfecting effect becomes better.
Irritable bowel syndrome (IBS) belongs to chronic functional gastrointestinal diseases featured by abdominal pain and changes in bowel habits. This study aimed to investigate the clinical significance of serum miR-148 expression in different subtypes of IBS. We enrolled 86 IBS patients and 55 healthy controls. miR-148 expression levels were assessed in IBS patients classified into IBS-constipation (IBS-C), IBS-diarrhea (IBS-D), and IBS-mixed stool pattern (IBS-M) subtypes. Receiver-operating characteristic (ROC) curves were employed to evaluate the diagnostic potential of miR-148 in distinguishing among IBS subtypes. Additionally, we analyzed the correlation between miR-148 expression and clinical characteristics, including IBS symptom severity. miR-148 expression was highest in IBS-D (diarrhea) group, followed by IBS-M and IBS-C. With the exception of the IBS-C group, miR-148 expression was elevated in IBS patients compared to controls. ROC curve analysis demonstrated that serum miR-148 exhibited higher diagnostic accuracy for discriminating IBS-C and IBS-D than IBS-M. Correlation analysis revealed a positive relationship between serum miR-148 relative expression and IBS symptom severity system scores. Univariate logistic analysis indicated a positive association between miR-148 expression and IBS-D and a negative correlation with IBS-C. miR-148 expression exhibits differential patterns among IBS subtypes and holds a potential to distinguish IBS-C and IBS-D. Furthermore, miR-148 expression correlates with the severity of IBS symptoms.
The PRI and DRI groups will receive an equal amount of treatment time, comprising 1.5 hours per day, 3 days per week, for 6 weeks. The PRI protocol provides robotic training for 45 minutes and impairment-oriented training for 45 minutes. The PRI group will start from the Bi-Manu-Track proximal mode (i.e., forearm) and then the Bi-Manu-Track distal mode (i.e., wrist).
This study explored how mental fatigue affects brain activity during a low-intensity bike task utilising a continuous wavelet transformation in electroencephalography (EEG) analysis. The aim was to examine changes in brain activity potentially linked to central motor commands and to investigate their relationship with ratings of perceived exertion (RPE). In this study, sixteen participants (age: 21 ± 6 y, 7 females, 9 males) underwent one familiarization and two experimental trials in a randomised, blinded, cross-over study design. Participants executed a low-intensity bike task (9 min; 45 rpm; intensity (W): 10 % below aerobic threshold) after performing a mentally fatiguing (individualized 60-min Stroop task) or a control (documentary) task. Physiological (heart rate, EEG) and subjective measures (self-reported feeling of mental fatigue, RPE, cognitive load, motivation) were assessed prior, during and after the bike task. Post-Stroop, self-reported feeling of mental fatigue was higher in the intervention group (EXP) (74 ± 16) than in the control group (CON) (37 ± 17; p < 0.001). No significant differences in RPE during the bike task were observed between conditions. EEG analysis revealed significant differences (p < 0.05) in beta frequency (13-30 Hz) during the bike task, with EXP exhibiting more desynchronization during the pedal push phase and synchronization during the pedal release phase. These results suggest that mental fatigue, confirmed by both subjective and neurophysiological markers, did not significantly impact RPE during the bike task, possibly due to the use of the CR100 scale or absence of a performance outcome. However, EEG data did reveal significant beta band alterations during the task, indicating increased neural effort under mental fatigue. These findings reveal, for the first time, how motor-related brain activity at the motor cortex is impacted during a low-intensity bike task when mentally fatigued.
Ototoxicity with use of Tobramycin for Injection 

Tobramycin for Injection can cause both auditory and vestibular eighth nerve damage. The auditory changes are irreversible, are usually bilateral, and may be partial or total. Symptoms of ototoxicity can include dizziness, vertigo, tinnitus, roaring in the ears and hearing loss. Ototoxicity symptoms may manifest during therapy or after tobramycin has been discontinued. The risk of ototoxicity increases with higher peak and trough serum tobramycin concentrations, in patients who receive high doses or prolonged or prior treatment with tobramycin or other aminoglycosides, in patients with renal impairment, patients receiving with other nephrotoxic or ototoxic drugs and in the extremes of age. To decrease the risk of ototoxicity, use as short a duration of therapy as clinically appropriate, adequately hydrate patients, limit the use of other ototoxic drugs, and closely monitor tobramycin concentrations during therapy [see Dosage and Administration (2.9)]. Monitor patients for signs and symptoms of auditory or vestibular toxicity and consider serial audiograms in high-risk patients. Discontinue tobramycin in patients with evidence of auditory or vestibular toxicity. 

Risk of Ototoxicity Due to Mitochondrial DNA Variants 

Cases of ototoxicity with aminoglycosides have been observed in patients with certain variants in the mitochondrially encoded 12S rRNA gene (MT-RNR1), particularly the m.1555A>G variant. Ototoxicity occurred in some patients even when their aminoglycoside serum levels were within the recommended range. Mitochondrial DNA variants are present in less than 1% of the general US population, and the proportion of the variant carriers who may develop ototoxicity as well as the severity of ototoxicity is unknown. In case of known maternal history of ototoxicity due to aminoglycoside use or a known mitochondrial DNA variant in the patient, consider alternative treatments other than aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe and effective alternative therapies.
Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between. After exercise, this group had to undergo vibration exercise by using whole body vibration machine.
The invention belongs to the technical field of pharmaceutical chemistry, and discloses an amide aromatic phenol antibacterial peptide mimic with anti-drug-resistant bacteria activity and no obvious toxicity and a preparation method thereof. The invention obtains the target product through 3-4 steps of reaction, and the main structure is shown as follows. In-vitro antibacterial activity experiments prove that most of compounds in the series have good activity on gram-positive bacteria staphylococcus aureus, enterococcus faecalis, gram-negative bacteria escherichia coli and stenotrophomonas maltophilia, and the compounds have excellent broad-spectrum antibacterial activity; meanwhile, in vitro erythrocyte hemolytic data show that the medicine has low toxicity and good selectivity. Some compounds also show excellent antibacterial activity against "superbacteria" including methicillin-resistant staphylococcus aureus (MRSA), clinical strains producing NDM-1 and KPC-2 enzymes, and the like. Therefore, the series of compounds are expected to be used as new antibacterial candidate drugs. 。
Mecamylamine HCl reduces blood pressure in both normotensive and hypertensive individuals. It has a gradual onset of action (1/2 to 2 hours) and a long-lasting effect (usually 6 to 12 hours or more). A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced.

Pharmacokinetics and Metabolism

Mecamylamine HCl is almost completely absorbed from the gastrointestinal tract, resulting in consistent lowering of blood pressure in most patients with hypertensive cardiovascular disease. Mecamylamine HCl is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine.

Mecamylamine HCl crosses the blood-brain and placental barriers.
FIELD: pharmacy. SUBSTANCE: method involves treatment of iron powder (particle size is 0.15-0.35 mm) with physiologically active polymer that is soluble in water and in organic solvent. This active polymer is used as solution at concentration 0.1-1.0 wt.-%. Obtained preparations of iron powder can be used for intravenous and intramuscular administration. Method can be used in chemical industry and medicine. EFFECT: hydrophilic property of iron powder surface, pharmacological property. 2 cl, 1 tbl
Cervical cancer is the first cancer deemed amenable to elimination through prevention, and thus lessons from the epidemiology and prevention of this cancer type can provide information on strategies to manage other cancers. Infection with the human papillomavirus (HPV) causes virtually all cervical cancers, and an important proportion of oropharyngeal, anal and genital cancers. Whereas 20th century prevention efforts were dominated by cytology-based screening, the present and future of HPV-associated cancer prevention relies mostly on HPV vaccination and molecular screening tests. In this Review, we provide an overview of the epidemiology of HPV-associated cancers, their disease burden, how past and contemporary preventive interventions have shaped their incidence and mortality, and the potential for elimination. We particularly focus on the cofactors that could have the greatest effect on prevention efforts, such as parity and human immunodeficiency virus infection, as well as on social determinants of health. Given that the incidence of and mortality from HPV-associated cancers remain strongly associated with the socioeconomic status of individuals and the human development index of countries, elimination efforts are unlikely to succeed unless prevention efforts focus on health equity, with a commitment to both primary and secondary prevention.
PROBLEM TO BE SOLVED: To especially effectively prevent the recurrence of acute cardiac infarction by administering both a platelet-inactivating agent, acetylsalicylic acid, and a direct thrombin-inhibiting agent, hirudin, into an acute cardiac infarction patient not subjected to a thrombolytic treatment. SOLUTION: Both (A) acetylsalicylic acid and (B) hirudin are administered. A hirudine mutant HIV of the formula [W is the phenolic hydroxyl group of Tyr (desulfatohirudin HIV) or a group of the formula: -O-SO3 H (hirudin HIV)], etc. When the component A is administered without changing its dosage, the daily dosage is preferably 80-100mg. The component A is preferably orally administered. When the component B is intravenously administered without changing its dosage, the daily dosage is preferably 0.1-0.15mg/kg body weight. Both the components A and B are preferably continuously administered for 3-6 months after the crisis of the acute cardiac infarction.
BACKGROUND/AIM: To investigate the factors related to non-reversal of ostomy after cytoreductive surgery in ovarian cancer. In many women with ovarian cancer, transitory ostomies are performed to limit the consequences of anastomotic leak. Although intended to be temporary, a proportion of these ostomies might never be reversed.
PATIENTS AND METHODS: This was a retrospective study of patients with 2014 International Federation of Obstetrics and Gynecology stage IIB-IVB ovarian cancer requiring a transitory ostomy during primary or secondary cytoreductive surgery at the Bergonie Institute, France, and the University Hospital of Las Palmas, Spain, between January 2012 and December 2022. Rate of ostomy reversal, its timing (weeks) and postoperative complications were assessed. Multivariate logistic regression analysis was performed to identify limiting factors for ostomy reversal.
RESULTS: During the study period, we reviewed data on 181 consecutive patients with ovarian cancer with transitory ostomy creation; 89 (49.2%) patients were not candidates for an ostomy reversal surgery because of disease progression (n=65), death (n=16), and patient's refusal of surgery (n=8). A total of 92 patients were candidates for reversal surgery and were therefore included in the final analysis. In total, 57 (62%) patients had their ostomy reversed. The mean time from ostomy creation to ostomy closure was 47.7 (standard deviation=33.1) weeks. Hartmann's procedure (leaving a rectal stump of 5-6 cm) was identified as an independent predictive factor for non-reversal of ostomy (odds ratio=6.42, 95% confidence interval=1.61-25.53; p=0.008). Complications after ostomy reversal occurred in 32 patients (34.8%).
CONCLUSION: Hartmann's procedure is a limiting factor for ostomy reversal in patients with ovarian cancer. We recommend avoiding Hartmann's procedure during cytoreductive surgery, even after colorectal anastomotic leak.
The invention relates to lamellar gels formed from fatty acids and aqueous substances. Preferably the gels are lamellar liquid crystals. A surfactant, with a hydrophilic lipophilic balance greater than or equal to 12.0 is also included. The gels foam when they are diluted and agitated in water and deposit fatty acid from solution. The fatty acid has a C10-C14 carbon chain length and is most preferably lauric acid. The surfactant may be an anionic surfactant chosen from alkyl sulphates, alkyl ether sulphates, fatty acid soaps and alpha olefin sulphonates; a non-ionic surfactant chosen from alkylpolyglucosides, sucrose esters or ethoxylated sorbitan esters; or an amphoteric surfactant chosen from betaines, sulphobetaines, propionates, glycinates or amphoacetates. Preferably the gels are used as shampoos or as washes for skin conditions, specifically as burn washes or antibacterial washes. Active ingredients, such as minoxidil, may be included. In an embodiment, lauric acid, water and ammonium lauryl sulphate are used and minoxidil is included as an active to treat male-pattern baldness.
Major screening abnormalities in precolposcopic stage are tests results that imply direct referral to colposcopy (and/or expedited treatment) without performing additional high-grade squamous intraepithelial lesions or worse (HSIL+) risk selection testing. Currently, both clinically validated HSIL+ risk selection tests, reflex cytology and reflex p16/Ki67 dual staining (DS), are being compared for use in primary human papillomavirus (HPV)-based screening to avoid possible overtreatment, but there is still no sufficient data available for their performance. Among 30 066 liquid-based cervical cancer screening tests results, a group of 332 women was selected with available high-risk types of HPV tests results with 16/18 limited genotyping, liquid-based cytology, DS, and histology results from standardized colposcopy with biopsy. In HPV 16/18+ cases, three triage approaches were retrospectively analyzed. Predictive values for detection of HSIL+ were calculated and number of colposcopies required in each strategy. Both triage models with DS used (reflex cytology followed by DS, and reflex DS alone in all cases) had significantly higher positive predictive value for HSIL+ than strategy with reflex cytology alone (44.2%/45.7% vs. 28.3%; p < 0.0001). In models with DS, less colposcopies were required (95/92 vs. 152) and less colposcopies were needed per HSIL+ detection (2.26/2.19 vs. 3.54). Only one HSIL+ case was missed in both triage models with DS incorporation. p16/Ki67 dual-stain may be an effective, alone or combined with cytology, triage test to detect HSIL+ in patients with major screening abnormalities in primary HPV-based cervical cancer screening. Performing cytology as the first triage test improves the strategy by enabling referrals to expedited treatment in selected cases.
Stabilization through belts is commonly used as an adjunct for treatment of musculoskeletal problems. Although this treatment is popular among clinicians, there is a paucity of evidence on its use for shoulder pathology. The objective of this double-blinded longitudinal randomized controlled trial (RCT) is to determine the clinical efficacy of stabilization belting applied to patients receiving rehabilitation treatment for shoulder impingement syndrome. The study population will include patients who have been referred to the physiotherapy department of the Holland Orthopaedic \& Arthritic Centre for conservative treatment. Patients will be randomized into the treatment and control groups. The primary outcome measure is the Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) questionnaire.